About the Evoke Studies
Research indicates that the investigational medicine (a medicine not approved for clinical use) evaluated in the evoke studies might be beneficial against mild cognitive impairment or early Alzheimer’s disease. It is not yet approved for the treatment of Alzheimer’s disease. The evoke studies will evaluate if the investigational medicine, which comes in the form of a small tablet that is taken orally, is safe and effective for the treatment of mild cognitive impairment or early Alzheimer’s disease.
If you decide to participate, you will be one of more than 1,840 participants globally on this 3-year journey and will receive regular clinic visits, health checks, and medical testing.
You will get access to expert guidance and facilities during the studies. You may also be compensated for travel and expenses.